Levicept to Present Phase II Data at ACR Convergence 2024
October 28, 2024 05:00 ET
|
Levicept
SANDWICH, United Kingdom, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for osteoarthritis, today...
Levicept Announces Positive Results of Phase II Trial of novel Neurotrophin-3 Inhibitor, LEVI-04, for the Treatment of Patients with Moderate to Severe Osteoarthritis
August 06, 2024 03:00 ET
|
Levicept
All primary and secondary efficacy endpoints met – significant analgesia across all measures for all dosesWell tolerated with no increase in incidence of rapid joint deterioration compared to...
Levicept Completes Recruitment in Phase II Clinical Trial of Neurotrophin Modulator LEVI-04
December 13, 2023 04:00 ET
|
Levicept
SANDWICH, United Kingdom, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for chronic pain indications,...
Levicept Appoints Eliot Forster as CEO
November 30, 2023 04:00 ET
|
Levicept
Leadership Team Strengthened as Clinical Development of LEVI-04 a Novel Neurotrophin Modulator for Osteoarthritis and Chronic Pain Advances SANDWICH, United Kingdom, Nov. 30, 2023 (GLOBE NEWSWIRE)...